Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The claims accurately describe the indication, recombinant gE antigen, adjuvant, and standard two-dose schedule in several respects. However, numerous mechanistic, comparative, efficacy-duration, and CDC recommendation claims are not established by the supplied label. The efficacy claim for people over 70 or with chronic conditions overgeneralizes the label’s varying results.
Category Scores
Accurate Statements
Shingrix is a recombinant vaccine indicated to prevent shingles and boosts VZV-specific immune response.
The label identifies SHINGRIX as a recombinant vaccine for prevention of herpes zoster and says it boosts VZV-specific immune response, which is thought to protect against zoster.
Shingrix contains recombinant VZV glycoprotein E antigen produced using genetically engineered Chinese hamster ovary cells, and pairs gE with AS01B.
Section 11 describes recombinant gE antigen obtained from genetically engineered CHO cells and identifies AS01B as the adjuvant.
AS01B contains MPL and QS-21, with MPL derived from Salmonella minnesota and QS-21 purified from Quillaja saponaria plant extract.
Section 11 specifies these adjuvant components and sources.
Shingrix provides protection against postherpetic neuralgia.
Sections 14.2 and 14.6 report efficacy against PHN in specified study populations and attribute the benefit to prevention of HZ.
Two intramuscular doses are given 2–6 months apart under the standard schedule.
Section 2.4 specifies two 0.5 mL intramuscular doses, with the second dose 2 to 6 months after the first under the standard schedule.
Unsupported Statements
Shingrix does not kill VZV directly; it suppresses reactivation; gE mimics the virus’s outer structure; and the vaccine avoids viral-replication risks.
The label describes a VZV-specific immune response and recombinant gE antigen but does not make these specific mechanistic or viral-replication claims.
AS01B boosts antigen presentation to T cells and B cells, generates high antibody levels and CD4+ T cells, and Shingrix-induced T cells target infected nerve cells.
The supplied label does not describe these immune mechanisms or cellular targets.
The older live Zostavax vaccine had 51% efficacy and provokes a milder infection-like response.
The label identifies ZOSTAVAX as a live vaccine but provides neither this efficacy figure nor the described immune-response characterization.
CDC recommends Shingrix for the stated age groups.
The label specifies SHINGRIX indications and dosing but does not state what CDC recommends.
Protection peaks two weeks after the second dose.
The supplied label sections do not specify when protection peaks.
Shingrix immunity wanes slowly and protection is sustained through year 10.
Section 14.5 reports long-term follow-up and HZ incidence rates, but does not characterize immune waning as slow or explicitly establish protection through year 10.
No routine Shingrix boosters are approved yet.
The label provides the two-dose schedule but does not state whether boosters are approved or recommended.
After exposure to chickenpox or shingles, vaccinated people need post-exposure options such as VariZIG if unvaccinated.
The label says SHINGRIX is not indicated to prevent primary varicella infection, but provides no post-exposure guidance and does not mention VariZIG.
AS01B’s components are described as a bacterial lipid and as coming from tree bark.
The label identifies MPL as derived from Salmonella minnesota and QS-21 as purified from Quillaja saponaria plant extract; it does not use these descriptions.
Contradictions
Important Omissions
The label’s indication is for adults aged 50 years and older, and adults aged 18 years and older who are or will be at increased risk due to immunodeficiency or immunosuppression; it also states that SHINGRIX is not indicated to prevent primary varicella infection.
Importance:
Moderate
For individuals who are or will be immunodeficient or immunosuppressed and would benefit from a shorter schedule, the label permits the second dose 1 to 2 months after the first, in addition to the standard 2-to-6-month schedule.
Importance:
Moderate
The broad statement that Shingrix is safe for immunocompromised people should be qualified: the label indicates use for specified at-risk adults and reports safety evaluations in immunocompromised populations, but does not establish an unqualified guarantee of safety for all such people.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The standard schedule and core indication are substantially represented, but the unqualified safety statement and unsubstantiated efficacy and protection-duration claims could lead readers to overestimate certainty or generalizability. The label reports different efficacy results across studies and populations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Several detailed immune-mechanism, comparative-vaccine, durability, and CDC recommendation claims are not supported by the supplied label; efficacy and safety are also stated too broadly.
Suggested Improvement
Restrict mechanistic and duration statements to what the label reports, present efficacy with the relevant study population and results, avoid attributing recommendations to CDC, and include the shorter dosing schedule for eligible immunocompromised individuals.